Interleukin-1 antagonism decreases cortisol levels in obese individuals

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 5, 2017, Pages 1712-1718

  Urwyler, Sandrine Andrea ^a   Schuetz, Philipp ^a,b   Ebrahimi, Fahim ^a   Donath, Marc Y ^a   Christ Crain, Mirjam ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CORTICOTROPIN; HYDROCORTISONE; INTERLEUKIN 1; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; FOLLITROPIN; HUMAN GROWTH HORMONE; IL6 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LUTEINIZING HORMONE; PROLACTIN; THYROTROPIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; FEMALE; HEADACHE; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; METABOLIC SYNDROME X; NAUSEA; OBESITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SALIVA LEVEL; SYSTOLIC BLOOD PRESSURE; VERTIGO; BLOOD PRESSURE; CHEMISTRY; METABOLISM; MIDDLE AGED; SALIVA;

ADRENOCORTICOTROPIC HORMONE; ANTIRHEUMATIC AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; FEMALE; FOLLICLE STIMULATING HORMONE; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; LUTEINIZING HORMONE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROLACTIN; PROSPECTIVE STUDIES; SALIVA; THYROTROPIN;

EID: 85019069577     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-3931     Document Type: Article

References (37)

1. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specificexcess deaths associated with underweight, overweight, obesity. JAMA. 2007;298(17):2028-2037.
2. World Health Organization. Fact sheet No 311, obesity andoverweight (online). http://www. who. int/mediacentre/factsheets/fs311/en/. Accessed 21 February 2017.
3. Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity, the metabolic syndrome: A cross-sectional study ofobese subjects and review of the literature. Obesity (Silver Spring). 2013;21(1):E105-E117.
4. Dunkelman SS, Fairhurst B, Plager J, Waterhouse C. Cortisolmetabolism in obesity. J Clin Endocrinol Metab. 1964;24:832-841.
5. Mü ssig K, Remer T, Maser-Gluth C. Brief review: Glucocorticoidexcretion in obesity. J Steroid Biochem Mol Biol. 2010;121(3-5):589-593.
6. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamicpituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci. 2006;1083:111-128.
7. Ma° rin P, Darin N, Amemiya T, Andersson B, Jern S, Bjö rntorp P. Cortisol secretion in relation to body fat distribution in obesepremenopausal women. Metabolism. 1992;41(8):882-886.
8. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol inthe metabolic syndrome: A hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692-2701.
9. Reinehr T, Kulle A, Wolters B, Knop C, Lass N, Welzel M, Holterhus PM. Relationships between 24-hour urinary free cortisolconcentrations and metabolic syndrome in obese children. J Clin Endocrinol Metab. 2014;99(7):2391-2399.
10. An K, Salyer J, Brown RE, Kao HF, Starkweather A, Shim I. Salivary biomarkers of chronic psychosocial stress and CVD risks:a systematic review. Biol Res Nurs. 2016;18(3):241-263.
11. Manenschijn L, Schaap L, van Schoor NM, van der Pas S, Peeters GM, Lips P, Koper JW, vanRossum EF. High long-term cortisol levels, measured in scalp hair, are associated with a history of cardiovasculardisease. J Clin Endocrinol Metab. 2013;98(5):2078-2083.
12. Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, Pettigrew RI, Nieman LK, Gharib AM. Hypercortisolism is associatedwith increased coronary arterial atherosclerosis: Analysis of noninvasivecoronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98(5):2045-2052.
13. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatorydisease. Nat Rev Immunol. 2011;11(2):98-107.
14. Donath MY, Dalmas É, Sauter NS, Bö ni-Schnetzler M. Inflammationin obesity and diabetes: Islet dysfunction and therapeuticopportunity. Cell Metab. 2013;17(6):860-872.
15. Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1family members in the pathogenesis and treatment of metabolicdisease: Focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75(2):280-290.
16. Di Renzo L, Bigioni M, Del Gobbo V, Premrov MG, Barbini U, Di Lorenzo N, De Lorenzo A. Interleukin-1 (IL-1) receptor antagonistgene polymorphism in normal weight obese syndrome: Relationshipto body composition and IL-1 alpha and beta plasma levels. Pharmacol Res. 2007;55(2):131-138.
17. Chae JS, Paik JK, Kang R, Kim M, Choi Y, Lee SH, Lee JH. Mildweight loss reduces inflammatory cytokines, leukocyte count, oxidativestress in overweight andmoderately obese participants treated for3 years with dietary modification. Nutr Res. 2013;33(3):195-203.
18. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, Schauer PR. The chronic inflammatory hypothesis for themorbidity associated with morbid obesity: Implications and effectsof weight loss. Obes Surg. 2004;14(5):589-600.
19. Dalmas E, Rouault C, Abdennour M, Rovere C, Rizkalla S, Bar-Hen A, Nahon JL, Bouillot JL, Guerre-Millo M, Clément K, Poitou C. Variations in circulating inflammatory factors are relatedto changes in calorie and carbohydrate intakes early in the course ofsurgery-induced weight reduction. Am J Clin Nutr. 2011;94(2):450-458.
20. Donath MY. Targeting inflammation in the treatment of type 2diabetes: Time to start. Nat Rev Drug Discov. 2014;13(6):465-476.
21. Mc Cann SM, Kimura M, Karanth S, Yu WH, Mastronardi CA, Rettori V. The mechanism of action of cytokines to control therelease of hypothalamic and pituitary hormones in infection. Ann NY Acad Sci. 2000;917:4-18.
22. van der Meer MJ, Sweep CG, Rijnkels CE, Pesman GJ, Tilders FJ, Kloppenborg PW, Hermus AR. Acute stimulation of thehypothalamic-pituitary-adrenal axis by IL-1 beta, TNF alpha andIL-6: A dose response study. J Endocrinol Invest. 1996;19(3):175-182.
23. Woloski BM, Smith EM, Meyer WJ III, Fuller GM, Blalock JE. Corticotropin-releasing activity of monokines. Science. 1985;230(4729):1035-1037.
24. Yasin S, Costa A, Navarra P, Pozzoli G, Kostoglou-Athanassiou I, Forsling M, Grossman A. Endothelin-1 stimulates the in vitro releaseof neurohypophyseal hormones, but not corticotropinreleasinghormone, via ETA receptors. Neuroendocrinology. 1994;60(6):553-558.
25. Goshen I, Yirmiya R. Interleukin-1 (IL-1): A central regulator ofstress responses. Front Neuroendocrinol. 2009;30(1):30-45.
26. Navarra P, Tsagarakis S, Faria MS, Rees LH, Besser GM, Grossman AB. Interleukins-1 and-6 stimulate the release ofcorticotropin-releasing hormone-41 from rat hypothalamus in vitrovia the eicosanoid cyclooxygenase pathway. Endocrinology. 1991;128(1):37-44.
27. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitaryadrenalaxis by cytokines: Actions and mechanisms of action. Physiol Rev. 1999;79(1):1-71.
28. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG. Release of multiple hormones by a direct action of interleukin-1 onpituitary cells. Science. 1987;238(4826):519-521.
29. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions:facts and hypotheses. Endocr Rev. 1996;17(1):64-102.
30. Crown J, Jakubowski A, Kemeny N, Gordon M, Gasparetto C, Wong G, Sheridan C, Toner G, Meisenberg B, Botet J. A phase Itrial of recombinant human interleukin-1 beta alone and in combinationwith myelosuppressive doses of 5-fluorouracil in patientswith gastrointestinal cancer. Blood. 1991;78(6):1420-1427.
31. Curti BD, Urba WJ, Longo DL, Janik JE, Sharfman WH, Miller LL, Cizza G, Shimizu M, Oppenheim JJ, Alvord WG, Smith JW, 2nd. Endocrine effects of IL-1 alpha and beta administered in a phase Itrial to patients with advanced cancer. J Immunother Emphasis Tumor Immunol. 1996;19:142-148.
32. Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects ofstatins: New therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):695-712.
33. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonistin type 2 diabetesmellitus. NEngl J Med. 2007;356(15):1517-1526.
34. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibitionand the prevention of recurrent cardiovascular events: Rationale anddesign of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605.
35. Zhang J, Rudemiller NP, Patel MB, Karlovich NS, Wu M, Mc Donough AA, Griffiths R, Sparks MA, Jeffs AD, Crowley SD. Interleukin-1 receptor activation potentiates salt reabsorption inangiotensin II-induced hypertension via the NKCC2 co-transporterin the nephron. Cell Metab. 2016;23(2):360-368.
36. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoidsinfluence stress responses Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55-89.
37. Jones TH, Kennedy RL. Cytokines and hypothalamic-pituitaryfunction. Cytokine. 1993;5(6):531-538.